Sponsor

Silence Therapeutics PLC

United Kingdom Office 205, 12 Hammersmith Grove, W6 7AP, United Kingdom

About the sponsor

Silence Therapeutics PLC’s clinical research is centred on polycythemia vera, a chronic myeloproliferative neoplasm characterised by excessive red blood cell production and elevated haematocrit.

Polycythemia vera
Myeloproliferative neoplasms
Haematocrit control

The sponsor’s activity in this area reflects a focused interest in blood disorders requiring ongoing clinical management and monitoring.

About Specializations

Silence Therapeutics PLC runs clinical trials in conditions such as Polycythaemia vera, among others.

Polycythaemia vera

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Quick filters

1 clinical trial

Polycythaemia vera

Not recruiting

Investigational

Study of SLN124 for Patients with Polycythemia Vera

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Tmprss6 Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
Sponsor:Silence Therapeutics PLC

Contact Research Centre

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →